FORM 8-A12B

 

 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 8-A

 

 

FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES

PURSUANT TO SECTION 12(b) OR 12(g) OF THE

SECURITIES EXCHANGE ACT OF l934

 

 

Tekmira Pharmaceuticals Corporation

(Exact Name of Registrant as Specified in Its Charter)

 

 

 

British Columbia   980597776

(State of Incorporation

or Organization)

 

(IRS Employer

Identification No.)

 

100-8900 Glenlyon Parkway

Burnaby, British Columbia, Canada

  V5J 5J8
(Address of Principal Executive Offices)   (Zip Code)

 

 

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), check the following box.  x

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), check the following box.  ¨

Securities Act registration statement file number to which this form relates: 333-169311.

 

 

Securities to be registered pursuant to Section 12(b) of the Act:

 

Title Of Each Class

To Be So Registered

 

Name Of Each Exchange On Which

Each Class Is To Be Registered

Common Shares, without par value   The NASDAQ Stock Market LLC

Securities to be registered pursuant to Section 12(g) of the Act:

N/A

(Title of Class)

N/A

(Title of Class)

 

 

 


 

Item 1. Description of Registrant’s Securities to be Registered.

The description of the common shares of the Registrant set forth under the heading “Description of Share Capital, Common Shares and Related Information” in the prospectus included in the Registrant’s registration statement on Form F-10 (File No. 333-169311) as intially filed with the Securities and Exchange Commission on September 10, 2010 (the “Registration Statement”), as subsequently amended by any amendments to such Registration Statement, is incorporated herein by reference.

 

Item 2. Exhibits.

Not applicable.


 

SIGNATURE

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Dated: November 4, 2010     Tekmira Pharmaceuticals, Inc.
    By:  

/s/    IAN C. MORTIMER        

      Ian C. Mortimer
      Executive Vice President, Finance and
      Chief Financial Officer